GLOBAL ORTHOBIOLOGICS MARKET FOR MUSCULOSKELETAL SOFT TISSUE REPLACEMENT AND REGENERATION

133 Pages | 50 Exhibits | 2017 Analysis | Forecasts Through 2021

OVERVIEW:
This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration. Markets covered include orthobiologics for cartilage replacement and regeneration, meniscus replacement and regeneration, and ligament and tendon replacement and regeneration. Products include allografts, scaffolds/matrices, and cellular therapies.

ORTHOBIOLOGICS MARKET HIGHLIGHTS

  • The global market for orthobiologic products for soft tissue replacement and regeneration totalled more than $1.1bn in 2016, with products for ligament/tendon replacement and regeneration accounting for the largest share of sales.
  • From 2016-21, the value of the market is projected to increase at a CAGR of 5.9%, reaching an estimated $1.4bn in 2021.
  • Each year, nearly 2 million people in the US suffer sports-related injuries and receive treatment in emergency departments. In the EU 28 countries, approximately 2 million people annually are admitted to hospital for sports injuries.
Key Questions Answered
  • What are the key drivers and limiters for the market?
  • Which competitors are leading the market and introducing new technology?
  • How are technological advancements impacting market growth?
  • Which areas of the market are experiencing dynamic growth?
  • How are mergers and acquisitions affecting the market shares of leading competitors?


TABLE OF CONTENTS:
Executive Summary

i. Surgical treatments
ii. Global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration
	a. Cartilage replacement and regeneration market 
	b. Meniscus replacement and regeneration market
	c. Ligament and tendon replacement and regeneration market 
iii. Methodology

Exhibit ES-1: Orthobiologic products for musculoskeletal soft tissue replacement and regeneration, combined market forecast ($m), 2016-21

1. Surgical Treatments For Musculoskeletal Soft Tissue Injuries or Disease

1.1 Incidence of sports injuries 
1.2 Prevalence of osteoarthritis 
1.3 Arthroscopy 
	1.3.1 Arthroscopic knee surgery
		1.3.1.1 Cartilage repair
			1.3.1.1.1 Surgical treatments
		1.3.1.2 Cartilage regeneration/tissue engineering
		1.3.1.3 Meniscus repair
		1.3.1.4 Nonoperative meniscal treatment
		1.3.1.5 Meniscectomy 
		1.3.1.6 Arthroscopic suturing of the meniscus
		1.3.1.7 Meniscal replacement 
		1.3.1.8 Cruciate ligament reconstruction
			1.3.1.8.1 Autografts 
			1.3.1.8.2 Allografts
	1.3.2 Arthroscopic shoulder surgery
		1.3.2.1 Acromioclavicular joint resection 
		1.3.2.2 Rotator cuff repair
		1.3.2.3 Thermal capsular shrinkage 
		1.3.2.4 Recurrent shoulder dislocation
		1.3.2.5 Bankart repair
		1.3.2.6 Superior labrum anterior to posterior lesion repair
	1.3.3 Other arthroscopic procedures
		1.3.3.1 Arthroscopic elbow procedures 
		1.3.3.2 Arthroscopic extremities procedures 
		1.3.3.3 Arthroscopic hip procedures
	1.3.4 Selected arthroscopy procedure volumes 
		1.3.4.1 US 
		1.3.4.2 5EU 
		1.3.4.3 Japan 
		1.3.4.4 China
1.4 Bibliography

Exhibit 1-1: Incidence of sports injuries treated in emergency departments, US, 2012 
Exhibit 1-2: Incidence of sports injuries, hospital patients, EU28, 2008-10 
Exhibit 1-3: Estimates of hospital-treated sports injuries, by type of sport, EU28, 2008-10 
Exhibit 1-4: Sports injuries, key facts and figures, EU28, 2008-10
Exhibit 1-5: Causes of articular cartilage injury
Exhibit 1-6: Outerbridge classification system for chondral damage 
Exhibit 1-7: Bucket handle tear of the medial meniscus 
Exhibit 1-8: Graft options for anterior cruciate ligament repair 
Exhibit 1-9: Conditions amenable to arthroscopic ankle surgery 
Exhibit 1-10: Conditions amenable to arthroscopic wrist surgery 
Exhibit 1-11: Arthroscopic surgery, US, procedure volumes forecast, 2015-21 
Exhibit 1-12: Arthroscopic surgery, France, procedure volumes forecast, 2015-21
Exhibit 1-13: Arthroscopic surgery, Germany, procedure volumes forecast, 2015-21 
Exhibit 1-14: Arthroscopic surgery, Italy, procedure volumes forecast, 2015-21 
Exhibit 1-15: Arthroscopic surgery, Spain, procedure volumes forecast, 2015-21 
Exhibit 1-16: Arthroscopic surgery, UK, procedure volumes forecast, 2015-21 
Exhibit 1-17: Arthroscopic surgery, Japan, procedure volumes forecast, 2015-21 
Exhibit 1-18: Arthroscopic surgery, China, procedure volumes forecast, 2015-21 

2. Orthobiologic Products for Soft Tissue Replacement and Regeneration

2.1 Cartilage replacement and regeneration 
	2.1.1 Allograft transplants
		2.1.1.1 Products 
	2.1.2 Cellular regeneration 
		2.1.2.1 Chondrocyte transplantation 
			2.1.2.1.1 Products
			2.1.2.1.2 Olympus Medical 
			2.1.2.1.3 Products withdrawn from the market
			2.1.2.1.4 Terminated clinical trials 
		2.1.2.2 Stem cells
			2.1.2.2.1 Products
			2.1.2.2.2 Emerging technologies 
		2.1.2.3 Growth factors
			2.1.2.3.1 Emerging 
		2.1.2.4 Gene therapy
		2.1.2.5 Scaffolds 
			2.1.2.5.1 Collagen
			2.1.2.5.2 Polymer
			2.1.2.5.3 Products
			2.1.2.5.4 Emerging products
			2.1.2.5.5 Products withdrawn from the market
			2.1.2.5.6 Terminated clinical trials 
2.2 Meniscus repair, replacement, and regeneration 
	2.2.1 Allograft transplants
		2.2.1.1 Products 
	2.2.2 Scaffolds
		2.2.2.1 Products 
	2.2.3 Meniscus replacement products
	2.2.4 Other emerging products
2.3 Tendon repair, replacement, and regeneration 
	2.3.1 Allograft transplants
	2.3.2 Scaffolds
		2.3.2.1 Products 
		2.3.2.2 Emerging products 
2.4 Bibliography

Exhibit 2-1: Selected cartilage allograft products, 2017
Exhibit 2-2: Carticel autologous cultured chondrocytes, 2017
Exhibit 2-3: Selected cartilage regeneration technologies no longer under development, 2017
Exhibit 2-4: Selected cartilage stem cell products, 2017 
Exhibit 2-5: Selected emerging stem cell products for cartilage repair, 2017 
Exhibit 2-6: Emerging growth factor technologies for cartilage restoration, 2017 
Exhibit 2-7: Selected cartilage scaffold products for cartilage reconstruction, 2017 
Exhibit 2-8: Selected emerging cartilage scaffold products, 2017 
Exhibit 2-9: Selected meniscus allograft products, 2017 
Exhibit 2-10: Selected meniscus scaffold products, 2017 
Exhibit 2-11: The NUsurface synthetic meniscus replacement product, 2017
Exhibit 2-12: Selected emerging meniscal replacement products, 2017 
Exhibit 2-13: Selected emerging meniscus allograft and regenerative scaffold products 
Exhibit 2-14: Selected tendon and ligament allograft products, 2017
Exhibit 2-15: Selected tendon and ligament scaffold products, 2017 
Exhibit 2-16: Selected emerging tendon and ligament allograft and scaffold products, 2017
 
3. Market for Orthobiologic Products for Musculoskeletal Soft Tissue Replacement And Regeneration

3.1 Cartilage replacement and regeneration products market
3.2 Meniscus replacement and regeneration products market
3.3 Ligament and tendon replacement and regeneration products market
3.4 Combined market forecast 
3.5 Competitive analysis
3.6 Bibliography

Exhibit 3-1: Orthobiologic products for cartilage replacement and regeneration, market forecast, 2016-21
Exhibit 3-2: Cartilage replacement and regeneration products market, share by country/region, 2016 
Exhibit 3-3: Cartilage replacement and regeneration product sales, by country/region ($m), 2016€"21
Exhibit 3-4: Reimbursement levels for orthobiologics for musculoskeletal soft tissue replacement and regeneration, US
Exhibit 3-5: Private insurance reimbursement coverage for cartilage and meniscus orthobiologics, US
Exhibit 3-6: Comparison of Carticel versus MACI's approved indications, US 
Exhibit 3-7: MACI's potential annual US market
Exhibit 3-8: Meniscus replacement and regeneration products, market forecast, 2016-21
Exhibit 3-9: Meniscus replacement and regeneration products market, share by country/region, 2016 
Exhibit 3-10: Meniscus replacement and regeneration product sales, by country/region ($m), 2016€"21
Exhibit 3-11 Ligament and tendon replacement and regeneration products, market forecast, 2016-21
Exhibit 3-12: Ligament and tendon replacement and regeneration products market, share by country/region, 2016 
Exhibit 3-13: Ligament and tendon replacement and regeneration product sales, by country/region ($m), 2016-21 
Exhibit 3-14: Orthobiologic products for musculoskeletal soft tissue replacement and regeneration, combined market forecast ($m), 2016-21
Exhibit 3-15: Orthobiologic products for musculoskeletal soft tissue replacement and regeneration, share by supplier, 2016

APPENDIX: COMPANY LISTING


COMPANIES COVERED:

  1. Active Implants LLC
  2. AlloSource
  3. Anika Therapeutics, Inc.
  4. Ars Arthro Biotechnology/Arthro Kinetics AG
  5. Arthrex, Inc.
  6. Aspect Biosystems Ltd.
  7. BioTissue AG
  8. Bone Biologics Corporation
  9. CartiHeal Ltd.
  10. Cartiva, Inc.
  11. Cellular Biomedicine Group
  12. Co.don AG
  13. ConMed Corporation
  14. Cytex Therapeutics, Inc.
  15. DePuy Synthes/Johnson & Johnson
  16. DSM Biomedical B.V.
  17. Educell d.o.o.
  18. Geistlich Pharma/Geistlich AG
  19. Heraeus Medical GmbH
  20. Histogenics Corporation
  21. ISTO Biologics
  22. Ivy Sports Medicine/Stryker
  23. Johnson & Johnson
  24. JRF Ortho
  25. Kolon Life Science Inc.
  26. LifeNet Health
  27. Mallinckrodt Pharmaceutical
  28. Medipost Co. Ltd.
  29. Medtronic Plc
  30. Mesoblast Ltd
  31. MiMedx
  32. Mitsubishi Tanabe Pharma Corporation
  33. Musculoskeletal Transplant Foundation
  34. Nature Cell Co. Ltd.
  35. Olympus Corporation
  36. OrthoCyte Corporation/BioTime, Inc.
  37. Orthonika Ltd
  38. Orthox LTD
  39. Osiris Therapeutics, Inc.
  40. Piramal Enterprises Ltd.
  41. Regentis Biomaterials
  42. RTI Surgical, Inc.
  43. Sanofi Group
  44. Scil Technology GmbH
  45. Smith & Nephew PLC
  46. Stryker Corporation
  47. Swedish Orphan Biovitrum AB
  48. SwissBiomed Orthopaedics AG
  49. TiGenix NV
  50. Tissue Engineering Technologies AG (dba TETEC)/Aesculap/B. Braun
  51. TissueGene, Inc.
  52. Tissue Regenix Group PLC
  53. Vericel Corporation
  54. Wright Medical Group N.V.
  55. Zimmer Biomet Holdings, Inc.
Contact Us

Need help finding medtech research? Let us help you!